Treatment protocols.

21 C.F.R. § 312.83
in effectEffective: 2024-07-01
Sign in to generate a plain English summaryAsk Belisarius Agent
If the preliminary analysis of phase 2 test results appears promising, FDA may ask the sponsor to submit a treatment protocol to be reviewed under the procedures and criteria listed in §§ 312.305 and 312.320. Such a treatment protocol, if requested and granted, would normally remain in effect while the complete data necessary for a marketing application are being assembled by the sponsor and reviewed by FDA (unless grounds exist for clinical hold of ongoing protocols, as provided in § 312.42(b)(3)(ii)).

Starting a business? Corpus forms LLCs in all 50 states and DC.